Cynthia Thurlow connects with Dr. Tracy Gapin today. He is a board-certified urologist and men’s health expert.
The current state of metabolic health in the United States and most westernized countries has sparked a great interest in a GLP1 agonist, AKA Semaglutide Ozempic. So I wanted to talk to a clinician actively utilizing this medication.
Dr. Gapin and I discuss what this drug class represents. (These are synthetic peptides.) We speak about Semaglutide, Ozempic, Wegovy, and oral Rybelsus. We get into current research, side effects, who should not take these medications, and the mechanisms of action specific to the pancreas and beta cells, reductions, gastric emptying, and the upregulation of satiety. We discuss changes in the brain regarding leptin and how these drugs work. We also talk about weight loss resistance, and I answer questions from listeners.
From my perspective, it all comes back to basics. I believe that if we are to prescribe these medications, we must help our patients understand how lifestyle impacts weight-loss resistance and metabolic health. I loved that Dr. Tracy spent some time talking about the specific ways he works with his patients, even before prescribing medications. He also explains how important he has felt this drug has been for his patients.
I approached today’s conversation with an open mind, and I hope you will do the same.
